Oedema, hypertension and cardiac failure have been reported in association with NSAID treatment. There is insufficient data to exclude such a risk for flurbiprofen oromucosal spray, solution.
The following list of adverse effects relates to those experienced with flurbiprofen at OTC doses for short-term use. (Very common (≥1/10), Common (≥1/100 to <1/10), Uncommon (≥1/1000 to <1/100), Rare (≥1/10000 to <1/1000), Very rare (<1/10000), not known (cannot be estimated from the available data)).
Blood and lymphatic system disorders: Not known: anaemia, thrombocytopenia.
Cardiovascular and cerebrovascular disorders: Not known: Oedema, hypertension, cardiac failure.
Nervous System disorders: Common: dizziness, headache, paresthesia. Uncommon: somnolence.
Respiratory, thoracic and mediastinal disorders: Common: throat irritation. Uncommon: exacerbation of asthma and bronchospasm, dyspnoea, wheezing, oropharyngeal blistering, pharyngeal hypoaesthesia.
Gastrointestinal disorders: Common: diarrhoea, mouth ulceration, nausea, oral pain, paraesthesia oral, oropharyngeal pain, oral discomfort (warm or burning feeling or tingling of the mouth). Uncommon: abdominal distension, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, glossodynia, dysgeusia, oral dysaesthesia, vomiting.
Skin and subcutaneous tissue disorders: Uncommon: various skin rashes, pruritus. Not known: severe forms of skin reaction such as bullous reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis.
General disorders and administration site conditions: Uncommon: pyrexia, pain.
Immune System disorders: Rare: anaphylactic reaction.
Psychiatric disorders: Uncommon: insomnia.
Hepatobiliary disorders: Not known: hepatitis.
View ADR Monitoring Form